NEW YORK (GenomeWeb) – PathoFinder said today that it has received CE marking for its RealAccurate TVMGres PCR Kit, a multiplex real-time PCR assay that enables the simultaneous detection of Trichomonas vaginalis or Mycoplasma genitalium in urine and vaginal samples. The test can also identify 23S rRNA mutations in M. genitalium that provide resistance to azithromycin, a first-line antibiotic.
T. vaginalis and M. genitalium cause infections that can have serious medical consequences, such as chronic urethritis in men and infertility in women. Azithromycin resistance in M. genitalium is increasingly a cause of therapy failure.
The test gives "a clear diagnosis quickly and easily" and leads to concrete advice on treatment, PathoFinder CEO Guus Simons said in a statement.
PathoFinder, located in the Brightlands Maastricht Health Campus, developed the test with NYtor, in Nijmegen, The Netherlands.